<SEC-DOCUMENT>0001341004-13-000920.txt : 20130913
<SEC-HEADER>0001341004-13-000920.hdr.sgml : 20130913
<ACCEPTANCE-DATETIME>20130913170046
ACCESSION NUMBER:		0001341004-13-000920
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130913
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130913
DATE AS OF CHANGE:		20130913

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DELCATH SYSTEMS, INC.
		CENTRAL INDEX KEY:			0000872912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				061245881
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16133
		FILM NUMBER:		131096948

	BUSINESS ADDRESS:	
		STREET 1:		566 QUEENSBURY AVENUE
		CITY:			QUEENSBURY
		STATE:			NY
		ZIP:			12804
		BUSINESS PHONE:		(518) 743-8892

	MAIL ADDRESS:	
		STREET 1:		566 QUEENSBURY AVENUE
		CITY:			QUEENSBURY
		STATE:			NY
		ZIP:			12804

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DELCATH SYSTEMS INC
		DATE OF NAME CHANGE:	19990607
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>
<head>
    <title>form8k.htm</title>
    <!--Licensed to: sasmf-->
    <!--Document Created using EDGARizer 2020 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>&#160;</div>

<div>&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 16pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 16pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 14pt; FONT-WEIGHT: bold">WASHINGTON, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 16pt; FONT-WEIGHT: bold">FORM 8-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt; FONT-WEIGHT: bold">CURRENT REPORT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt; FONT-WEIGHT: bold">PURSUANT TO SECTION 13 OR 15(D) OF THE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt; FONT-WEIGHT: bold">SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">Date of report (Date of earliest event reported): <font style="DISPLAY: inline; FONT-WEIGHT: bold">September 13, 2013</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman Bold, Times New Roman, serif; FONT-SIZE: 16pt; FONT-WEIGHT: bold">DELCATH SYSTEMS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt">Delaware</font></div>
</td>
<td valign="top" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt">001-16133</font></div>
</td>
<td valign="top" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt">06-1245881</font></div>
</td>
</tr><tr>
<td valign="top" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt">(State or Other Jurisdiction</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt">of Incorporation)</font></div>
</td>
<td valign="top" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt">(Commission File Number)</font></div>
</td>
<td valign="top" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt">(IRS Employer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt">Identification Number)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">566 Queensbury Avenue, Queensbury, New York, 12804</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">(Address of principal executive offices, including zip code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">(518) 743-8892</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">(Registrant&#8217;s telephone number, including area code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">NONE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">(Former name or former address, if changed since last report)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<div style="LINE-HEIGHT: 0pt; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Item 8.01. Other Events.</font></div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">On September 13, 2013, Delcath Systems, Inc. (&#8220;Delcath&#8221;) issued a press release announcing that it has received a "Complete Response" letter from the U.S. Food &amp; Drug Administration for the New Drug Application for Delcath&#8217;s Melblez<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">TM</font> Kit (Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System) for the treatment of patients with unresectable ocular melanoma metastatic to the liver.&#160;&#160;A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</font></div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="3">&#160;</font></div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="3">&#160;</font></div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Item 9.01.&#160;&#160;Financial Statements and Exhibits.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">The following exhibit is filed herewith:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">(d) Exhibits.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="12%" style="BORDER-BOTTOM: black 0.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Exhibit&#160;No.</font></div>
</td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="65%" style="BORDER-BOTTOM: black 0.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Description</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt">99.1</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt"> </font>
<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">Press Release of Delcath Systems, Inc., dated September 13, 2013</font></font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt">DELCATH SYSTEMS, INC.</font></div>
</td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt">Dated: September 13, 2013</font></div>
</td>
<td align="left" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt">By:&#160; </font></div>
</td>
<td align="left" valign="top" width="40%" style="BORDER-BOTTOM: black 0.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt">/s/&#160;&#160;Peter J. Graham</font></div>
</td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt">Name:&#160; </font></div>
</td>
<td align="left" valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt">Peter J. Graham</font></div>
</td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt">Title:&#160; </font></div>
</td>
<td align="left" valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt">Executive Vice President, </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt">General Counsel</font></div>
</td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt; FONT-WEIGHT: bold">EXHIBIT INDEX</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Exhibit No.</font></div>
</td>
<td valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Description</font></div>
</td>
</tr><tr>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt">99.1</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt"> </font>
<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman, serif; FONT-SIZE: 12pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">Press Release of Delcath Systems, Inc., dated September 13, 2013</font></font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
    <title>ex99-1.htm</title>
    <!--Licensed to: sasmf-->
    <!--Document Created using EDGARizer 2020 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: center"><img src="logo.jpg" alt="Delcath Logo"></div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div>
<div style="LINE-HEIGHT: 0pt; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt; FONT-WEIGHT: bold">DELCATH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR MELBLEZ<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">TM</font> KIT NEW DRUG APPLICATION</font></div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">NEW YORK,</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">NY</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8211;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">September 13</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">, 2013</font> &#8211; Delcath Systems, Inc. (NASDAQ: DCTH) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) received September 12, 2013 regarding the New Drug Application (NDA) for Delcath&#8217;s Melblez<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">TM</font> Kit (Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System) for the treatment of patients with unresectable ocular melanoma metastatic to the liver.</font></div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">A CRL is issued by the FDA when the review of a file is completed and questions remain that precludes approval of the NDA in its current form.&#160;&#160;The FDA comments included a statement that Delcath must perform another &#8220;well-controlled randomized trial(s) to establish the safety and efficacy of Melblez Kit using overall survival as the primary efficacy outcome measure,&#8221; and which &#8220;demonstrates that the clinical benefits of Melblez Kit outweigh its risks.&#8221; In addition to the FDA requirement to conduct an additional clinical trial(s) using the product the Company intends to market, Delcath is evaluating the other requirements contained in the letter, and will review potential regulatory paths forward with the FDA.</font></div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">About Delcath Systems</font></font></div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 12pt">Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Our proprietary drug/device combination product, the Delcath Hepatic Delivery System, is designed to administer high dose chemotherapy and other therapeutic agents to the liver, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. Outside of the United States, our proprietary product to deliver and filter melphalan hydrochloride is marketed under the trade name Delcath Hepatic CHEMOSAT&#174; Delivery System for melphalan hydrochloride. The Company obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT Delivery System for Melphalan in April 2012. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT Delivery System for Melphalan in Europe. In addition, the Company has initiated plans to investigate the Melblez Kit for primary liver cancer. For more information, please visit the Company's website at www.delcath.com.</font></div>

<div style="LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 11pt">Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to:&#160;&#160;the Company&#8217;s ability to satisfy the requirements of the FDA&#8217;s Complete Response Letter and provide the same in a timely manner, adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver and filter melphalan in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with primary and metastatic disease in the liver, market acceptance of the Gen Two CHEMOSAT system and patient outcomes using the same, approval of the current or future chemosaturation system for delivery and filtration of melphalan, doxorubicin or other chemotherapeutic agents for various indications in the US and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, our ability to successfully enter into strategic partnership and distribution arrangements in foreign markets including</font></div>

<div style="LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 11pt">&#160;</font></div>

<div style="LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 11pt">&#160;</font></div>

<div style="LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 11pt">Australia and key Asian markets and timing and revenue, if any, of the same, the approval of the Hepatic CHEMOSAT Delivery System device to deliver and filter doxorubicin in key Asian markets and patient outcomes using the same, our ability to obtain reimbursement for the CHEMOSAT system, uncertainties relating to the timing and results of research and development projects, uncertainties relating to the timing and results of future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.</font></div>

<div style="LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="top" width="72%">
<div style="LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times, serif; FONT-SIZE: 11pt; FONT-WEIGHT: bold">Contact Information:</font></div>

<div style="LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times, serif; FONT-SIZE: 11pt">&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="32%">
<div style="LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times, serif; FONT-SIZE: 11pt">Investors:</font></div>
</td>
<td align="left" nowrap valign="top" width="40%">
<div style="LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times, serif; FONT-SIZE: 11pt">Financial Media:</font></div>
</td>
</tr><tr>
<td align="left" nowrap valign="top" width="32%">
<div style="LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times, serif; FONT-SIZE: 11pt">Michael Polyviou/Patty Eisenhaur</font></div>
</td>
<td align="left" valign="top" width="40%">
<div style="LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times, serif; FONT-SIZE: 11pt">John Carter</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="32%">
<div style="LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times, serif; FONT-SIZE: 11pt">EVC Group&#160;</font></div>

<div style="LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times, serif; FONT-SIZE: 11pt">(212) 850-6020/(951) 316-0577</font></div>
</td>
<td align="left" valign="top" width="40%">
<div style="LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times, serif; FONT-SIZE: 11pt">EVC Group</font></div>

<div style="LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times, serif; FONT-SIZE: 11pt">(212) 850-6021</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 12.55pt; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>DELCATH LOGO
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`@$!
M`@("`@("`@(#!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*#0H*"PP,
M#`P'"0X/#0P."PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`&(!
M&`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*_%O_@X
M&_X*W?M`?L.?MP:9X.^&'CJ/PWX<N?"MIJ4EJVB:?>DW$EQ<HS[[B!WY6-!@
M'`QTY-?M)7\W?_!U#J37W_!4*.(R"067@_38@O\`SSS)</C_`,?S^-?4<(X:
ME7Q_)5BI+E>C5UT[G@\1UZE+"<U.33NMG8\[_P"(CC]L;_HK4/\`X2FC?_(E
M26?_``<??MB6UU'(_P`5+6X1#DQ2>%=("/[';;`X^A!KZL_X-.OV?O!WQ@MO
MCE?>+_"/A?Q4MBVBP6?]KZ;#??9MPOFDV"56"[L)DCKM'I7Z`?\`!2O_`((U
M_!C]J?\`9H\4Q:/X`\+>$_&^E:9/=Z#J^B:;%I\T=S&C/'%*(@HEB=AM97!P
M&)&&`-?38W,LIPN->#JX6.EDY<L>J3VMYG@X7`YC7PJQ,*\M;Z7?1V[^1\@?
M\$O_`/@Z!NOBQ\3='\!_'S2=#TB36YDL[+Q7I:M;VT<['"+=PL6"*Q('FHP5
M21E`N6'[+U_$N05)!R"*_JI_8Y_;PT?P=_P1N\`_&_XDZI)%8:-X/ADU6Z/S
M3WL]N3:[5!/S2S2Q@*,C+R#IUKR^+,AI8>5.MA(VYWR\J[]+>O8]#A[-ZE93
MI8B5^57N^W6_H?7]%?S2?M6_\'$'[2W[7/Q.DTSX>:MJ'P\T+4;H6ND:'X:A
M$FIS[F"QJ]P%,TDS''$6P9.`O<\K\5OVS/V]_P!A37]%OO'WC?XS>%)M70RV
M"^))Y+JVO`N-RA)]\;,-PW*1N&X9`S7-3X+Q3252I&,GM%MW_+[[7-I\44+M
MPA)Q6[MI_7K8_J%K\*/^"VO_``6B_:._9%_X*+>,O`/PZ\?P:!X5T6UTYK:S
M_L'3;LH\ME#+(3)/`[DEW)P6P!C&*^OO^"$G_!:N]_X*0Z=K/@;Q]9Z?IWQ-
M\,68OQ<62>5;:[9[UC:81Y/ERQNR!U'RGS%90.57\??^#@[5UUK_`(*^?&*1
M=F(;C3K?Y3D9CTRT0_CD?G6_#63^SS.IAL;!/EBW9I-;JS5S+/,RY\#"OA9M
M7ET;3V=T?L+_`,&Z'[<?Q=_;Q^`OQ"\2_%CQ0/$]SI&OQ:9IL@TRTL1`@MUD
MD&+>*,-DR*<MDC':OT6K\O\`_@U`T%-"_P"";WB;49`L8U+QS>REV^4;$L[)
M.OH"K?F:^0/^"J7_``<K?$3QQ\5]9\'_``#U:/PAX*T:XDL_^$AA@CEU'7&5
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M]IKQA_P49_95\"Q^,_B/XM^-WA?P_<SI`;YO$;-!#(QPJNL$K"+<1@!@N3]:
MK#<*5:D8<]:$7))I-ZZZ[6W%7X@A!RY:4FHWN[::>9_3-7%?M$_'KP_^R_\`
M!#Q-\0?%3WB>'O"=DU_?&UA\Z;RU(&$3(W,20,9'UK\-O^"+O_!>SXT:C^UO
MX,^&7Q3\22>/O"?CB_CT>*ZU"*,:AI=Q+\L,BS*`9$,FU663<<,2"",%W_!R
MO^V_\7O"O[7WB[X3:3XOU>T^&&H>'M.34-&CMH_LLS2+YK!G*;LEMAX;L!ZT
M4N%,0L?'!U6K-<U]=5=)VTW]0GQ!1>$>)II[VMV=M.NQ].Z)_P`'3WA#XP?M
M`>#O`GP]^%OB&\3Q;K]EHPU/7M1BL1`L\Z1&00Q"8L0&R`7&<=J_5^OXK_A[
MXSUGX<^/-&\0>';J:QU_1+V&^TZYA0/)!<1N'C=0002&`(R#R*_?+_@VD_;5
M^-/[8&N?%\_%GQGKGBF#08-*&FQZA:QPBW:5KOS&4HBYR(T!!ST'2O3XDX8I
M8:A]8PME&*UNVVVVEZ?D<&1Y[4KU?8U]7+:R5E9-_P!;GP'^T!_P<*_M;>$/
MCSXWTG2?BA#8Z5I>O7]I9V__``C.D2^1#'<2)&FYK4LV%`&6))QSFOW-_P""
M2WQF\9_M$_\`!._X8^./B#J_]O>+O$UA->WM[]D@M1,#=3"+]W"B1KB(1K\J
MC.,GDDU_*E\?]1.L?'CQM>%D<W>OWTVY?NG=<2'(]N:^G_%'_!<KXWZ3^S]\
M/_A?\./$5W\-?"?@70+;26;2F4:AJLZ)^]N)+@C>@9RVU(RH`QDL>:]O..&X
MXG#TZ>$A&#O=NR6EO)7=V>7EN=RH5ISQ,Y25M%=O6_F[']3=%?R<?#C_`(+2
M_M3?#+Q3;:M9_&SQSJ4ENZL;?6+XZG:R@')5HI]ZD'H<`'!X(ZU_1[_P2M_;
ME'_!0_\`8K\+_$FXL(=*UJZ:;3]9LX23##>P/LD,><D(XVR*"20)`"3C)^(S
MCAO$9?!59M2BW:ZZ,^IRS.Z.,FZ<4TUKJ?15%%,FF2VB>21TCCC!9F8X50.I
M)["OGCVA]%>.>/OVX/!7@N\>UM9;O7;B,[6-D@,(/^^Q`/\`P'(K$T#_`(*%
M>%=0NUCO]*UC3HV./-`295]R`0?R!KKC@,0US*#,G7A>USWZBLKP?XXTCQ_H
ML>H:+J%MJ%F_&^)L[3Z,.JGV(!K5KEE%IV:-$[[!1112&%%%%`!1110`5_,U
M_P`'-^JG4/\`@K+XHA+%A8Z'I4`X'&;59,?^/_K7],M?RQ_\'!'B9?$__!77
MXONCATLKFQL@1ZQZ?;*P_!MP_"OL^!H7Q\I=HO\`-'S'%<K82*[R7Y,_1/\`
MX-`=+$7P.^-%]@9N-=TZ#[N/N6\K=>_^LZ=OQK])/^"@?[2VB_LB_L;_`!!\
M>:Y>06D>E:/<)9([`-=WLD;);P(#]YGE91@=!D]`2/YA?V,O^"J/QM_8#\'Z
MOH/PN\46F@Z7KMXM_>12Z5:WIDF"!`P::-BOR@#`('%<Y^UG_P`%`OC)^W7J
MUG/\3_'.K^*4L7+6=B52WLK5B,;H[>%5C#D<;MNXCC)KW,=PI6Q692Q-225-
MM/K>R2TVMT[GE87B&EA\"J$(MS2:Z6U;\_T/&2Q8DDY)K]=/^"JT7B#]GW_@
MWX_92^'MR);+_A(I8M3U*$Y5L&"6[CB<=>&NE)!Z-&/2O+?^".7_``07\>?M
M<?%'0_&OQ.\/:EX2^$FE3I>RIJ4#6]WXFV,"MO#$P#B%B,/*0!MR$RQROZS_
M`/!>;_@GMJ_[>7["DFC^#+-+CQAX&O4US1+!-L?VY4B>*6T3.`&:)R4'`+QH
M.`<UMG&=X59AAZ',FHRO)]$[-+[KW?8QRW*Z_P!3K5;-.4;)=6KW?Y:=S^>/
M_@GKK/Q:\*_M2Z'K?P1\-R>)_B+H<5Q=Z=:QZ4FIM$OE-')*(7!!*JYPV,J2
M",$`U]?_`+;%C_P4-_X*"_#K3/"WQ-^$'BW5=)TC41JEJ+7P?':2QS"-X\[T
M4-M*R-E<X)QZ"OA_X$_&_P"(?[!?[1^G>+/#CWWA3QSX/NG1H+VU9'C)4I+;
MSPN`2K*65D8`X/8@$?HY+_P=T_&%O#:01_#'X<)JP3#W327C0,<?>$7F@CZ;
MS7IYG2Q;Q$*^%HPG9:2>Z]/+T\SAP-3#^QE2Q%64==EL_P#@DO\`P;X_\$]/
MCO\`LX_\%)=#\3^-?AAXS\(>&X-%U*"[OM2L7MX"7APD98\$E]I`]L]J^-/^
M"U6M?V]_P55^.4^XMY?B:6VSD'_5(D6./397[N_\$%/VU?BI^W_^S7XN^(OQ
M/OM+G>7Q,^EZ1:Z?8):6]I!#;PLX4#+MEY>KLQ^7C%?ST_\`!1[Q3_PFG_!0
M+XUZGO\`,6Y\;ZOM;.0RK>2J#GTPHKSLFQ%:OFU:6(24H147R[;WZG;F=&E2
MRZE&BVXRDWKOM8_7W_@EWKU]\)O^#9/XH^(=+<V^H-IWBBZAE`*LC;&@W@CN
M`O![$#TK\*O"&BQ>(_%FEZ=/<+:07]W%;R3GI"KN%+GZ`Y_"OZ1?^"%GP3T[
MXQ?\$)=#\%ZLDD>F>.++7]/NFP&81W%W=0LZY[@'(]Q7\_?[8G['GCC]ASXY
MZQX#\=Z1<Z=J.FS.+6Y,;"VU6WW82Y@?H\;C!X.5)*G#`@:</XFF\;BZ-[3<
MV_5:K\/U)SBA-8;#5+>[RI?/1_B?UI_L[_LO^`_V7OA%I'@OP3X;TG2-"TNU
M2W5(;9`]WA<&65L9DD<Y9G8DL6)JUXA?X?\`[*_@+Q3XPNK/P[X+T&R@?5M=
MO[>SCM4=8DYEE\M09&"C`ZL>`,G`K^<3X+?\'(W[4'P4^%>G>$[?7O#6OVVD
MVZVMI?:UI`N;^.)1M13(KJ)-H`&Z0,QQR37Z'M_PN[_@I5_P;?\`C#7-;U2\
M\5_$/QK-/K-O!;VL4#75E9ZFA^R0Q0JHYCM9-J@%F8XY)KY#&\-XK#SC/&5%
MRSFHMW=W=[ZKIOJ?1X;.Z%:#CAH/FC%M*RZ+;]-#QK]JG_@[1U*VUR_TSX'_
M``WTFTTJ.5_*UCQ,7>6Z)8DRBUA9`F[D_-(Q.<D`Y%?"'[9'_!1[]IS_`(*&
M_"RYO_'NIZYJ'PXTFZBEGBTS1_L6AVTY8K%YKQH`[;F(42NQSTY%?/7P9\8:
M;\*_C1X9UWQ#X;M?%6D^']6M[S4-"O6,<.J112JTEM(<'`<*5.0>O((XK[S_
M`."K'_!>BQ_;Z_9LL/A+X-^%UOX`\)V][;WTSR7JRR$PAMD,444:1QQ@L#_$
M3M&`._W5+*:.#K4XX3#J7>;:O'[];^ECY2>85<32F\16:[12W^[2WJ?/'_!'
M#2#K?_!4GX%P!0P3Q;:3D<=(V,G?_=K]R/\`@YTUN+1/^"47B6$I&)-8U[2K
M/=M&X[;@38SCTA_STK\8/^"".FIJO_!7/X+1N2!'J5U,.`<E+"Y<?JM?LK_P
M=!?#O6?'O_!+J\N=(LKB\B\->)K#5]1$*EC%:A)X6D('\*O/&2>@&2<`9KQL
M^DO[<PJ?3E_]*?\`D>EE$7_96(:7?\D?B-_P1ETR+5O^"IWP-AF4,@\4V\N,
M`@E`SCK[J*_J_P!5>+0]&O;F...+R(7D)50OW5)K^-#X&?&KQ#^SG\8?#?CO
MPG>)8>(_"E_%J-A.\:RHLJ'(#*>&4C((/4$BOZ`O^"3O_!2SXM?MQ_L/?M"?
M$[XFW6A1V'A"QN;72HM*T\6D4+PZ=+<7#$EF9CAX.K8&.V:CC3+*M64,5%KE
MBDO.[?\`P2^%\=3IQE0:?,VWY62_X!_/#XJU0ZYXHU*])+&\NI9\GDG<Y;^M
M?TH_\$./^"8WPM^$_P#P3[\$^(=<\#^'/$7B_P"(^E1ZWK%_K&G0WLICN!OB
MMT\Q3LB6)D!5>&;<QSD8_F?K^Q_]CC15\-?LB_"O3D4*MAX0TFW`!R!MLH5Z
M]^G6M^.,5.GAJ=.F[<SUMY+_`()CPK0A.O.<U>R_/_AC^5'_`(*7?"G0O@=^
MW_\`&#PEX9LDTWP_H7BF]MM/M$)*6L/FDK$N?X5!VC/8"OWF_P"#7K1_[,_X
M)4:3/C']H^)=4N/O9Z2)%^'^K_SFOP>_X*?^)E\8_P#!1GXY:C')YD<_CC5@
MC9S\JW<B`?@%`_"OW,_X(F?'/1OV5O\`@A=X%\7ZQ;WVH6D-[JA^SV*(9YY'
MU.Y`4;V5<@`G)8<#`R<`UQ0ISRFC#>3<5\^5BR%QCF-26R2E^:/TFKX[_:K_
M`&B]0^*OBI_"'AIYI-*BF^SO]GR7U.;.,#'5`>`.Y&>>,>H_%']J&P\2_LDV
MWC'0/M=HOBR+[-8K<*$G@9BRR!@I(W*$D&5)&0"">*Y7]ASX3V/AWPO>>/\`
M6A%$%61;-Y?NV\*`^;-]205SV"GUKX+!TE1A*O56J=DO,^UJ3YVH0>CUOY%3
MX5_\$^GOM.BN_%NI36DLH!^Q66TO'[/(01GV`(]ZZ/Q3_P`$\_#EW8-_8^KZ
MM8W8!VFX*3QL>V0%4C\#7E_QE_:Y\4?%3Q(^G>&);_3-*+F.WBL]PNKO_:8K
M\P)_NKT]ZYW3/BQ\2_@EK$%Q=W?B"U$AW?9]565X;@=QMD^O5<'GJ*[_`&6-
ME[[J)-]/Z_X)CS4EHHW7<F@;QE^QM\3XS*K1A^656+6FIP@\@'O^6Y2>W?[5
M^'?CVP^)W@VQUO37+6M]'NVG[T3#AD;_`&E.0?I7F7VK1OVV/@-.J116NKVV
M<(QRUC=!<@@]2C?J">XX\X_8&\?7/AWQKJ_@V_+1K<AIX8GX,4\?RR+CU*\G
M_KG7+BH_6*3G)6J0W\T:4WR223]U['UA1117B'8%%%%`!1110!!>:C;:<JFX
MG@@#<`R.%!_.O)_&/[)OP*^(7B>]UK7OAU\+=:UC49/.N[V^T6RN+FY?&-SR
M.A9C@#DGM78_%?2K[5+*V6RT.WUIEDRRRS+&(Q@\_,PS7#_\(?K_`/T(6G_^
M!L7_`,<KLP\6ES1GROU2_4QJI2TE&_R*W_##7[.7_1)_@[_X3NG_`/Q%;?@7
M]F3X)_##5TU#PWX!^&6A7\3!TN;#1K*WF0CH0ZH&!^AK-_X0_7_^A"T__P`#
M8O\`XY1_PA^O_P#0A:?_`.!L7_QRMY.<E9U6_P#MY?YF<:<$[J"^[_@'K'_"
M3Z;_`-!&Q_[_`*?XT?\`"3Z;_P!!&Q_[_I_C7D__``A^O_\`0A:?_P"!L7_Q
MRC_A#]?_`.A"T_\`\#8O_CE8?5X?S?BO\S7VC[?F6_CA^RQ\$OVEIEF\?^!_
MAYXOND4*MSJFGVUQ<*`,`"5AO``Z8->9:1_P20_9&T2\$\/P;^&#N.UQ;)<)
M_P!\R,R_I7H7_"'Z_P#]"%I__@;%_P#'*/\`A#]?_P"A"T__`,#8O_CE=-.I
M5A'DA5:792LOS,)T:4GS2IIOT_X!W?PY\+>"/@_X5@T+PG8>&/#.BVQ+16.E
MQ06EM&3U(2/"Y)ZG&37`ZK^QA^S[KNJ75]??"_X2WE[>RO<7$\V@V$DDTCDL
MSLQ3+,2223R2:?\`\(?K_P#T(6G_`/@;%_\`'*/^$/U__H0M/_\``V+_`..5
MG&+BW*-1IOS7^9;C%I)QV\O^`=_X#T3PA\+?"EIH7AJV\.^']%L0PMK#3DAM
M;:#<Q=ML:85<LQ)P.22:R?C'\*/AK^T/X:&C^/-`\&^,=+5BR6VL6UO>1QL<
M?,HD!VG@<C!XKEO^$/U__H0M/_\``V+_`..4?\(?K_\`T(6G_P#@;%_\<J52
M2ESJ>O>ZO^8VTX\KCIZ'G^D_\$E/V1]&U+[5#\&_A@\N<XGM4GCZY^X[%?TK
MZ$\'V7A7X>>&+/1-`BT'1-&TZ/RK6QL!%;6ULF<[41,*HR2>!WKSO_A#]?\`
M^A"T_P#\#8O_`(Y1_P`(?K__`$(6G_\`@;%_\<K2LYU;>UJN7K)/\V12IPI_
MPX)>BM^A@_&+_@G7^S5\?O%$^N>+_A?\-]8UFZ8O/?-9PQ7%PQZM(\95G/NQ
M)JWX2_8%_9O\"^&I]'TKX4?"6UTZY=9)H3HMG()F7[K.74EB.V2:T_\`A#]?
M_P"A"T__`,#8O_CE'_"'Z_\`]"%I_P#X&Q?_`!RJ]I5Y5'VKLNG-_P`$7L:7
M-S>S5_3_`(!>\!?LN_!+X4^+;77O#'@'X9^'M<L=WV;4--TBSM;F#<A1MLB*
M&7*LRG!Y!([UZ'J&K:+K%A/:7=UI=U:7,;130RR1O'*C##*RG@J02"#P0:\N
M_P"$/U__`*$+3_\`P-B_^.4?\(?K_P#T(6G_`/@;%_\`'*QG3YWS3G=^;7^9
MI&T5:,;?(X/6_P#@D]^R7XAUV34KKX.?"\W4C^8WE6D<,;-G.3&A"<GVYKU[
MX>?!;X6_"7X:77@SPOX;\$Z!X2OQ*MUH]A:6\%E="5=DGF1*`K[U`5MP.0,'
M(KG?^$/U_P#Z$+3_`/P-B_\`CE'_``A^O_\`0A:?_P"!L7_QRM:DZE1*,ZK:
M7>2?ZD0I4X.\8)/R7_`*W_##7[.>W'_"I_@]C_L7M/\`_B*]:T[5=%TBPM[2
MTNM,MK2UC6*&**1$CB10`JJ`<`````=,5Y=_PA^O_P#0A:?_`.!L7_QRC_A#
M]?\`^A"T_P#\#8O_`(Y6=2#J6YZE_5I_J5!*/PQM\O\`@')_&'X'?LW>%-3G
MO]7^$OPZU[6-3D>ZG^S^%[*ZN)W=BS22.4QEF))+-DDD\UN_"7QS\*=?\&1>
M`['P=I_ACPZI/D:-<:3!;Z<27\SY43,:MO);L=W(YKG?BE\3(/@P8#XC\&0Z
M?#<#,<^?,A8Y^[O5BH;V)S67\/?C[H_Q6U^/3/#WA.#4[M^2L0.V,?WF8G"C
MW)%=BH3E2YGS-+KS:+]#)."GHDK^16_;KFL;"Q\(>'/#]O:0:3IL$KQVUA&J
MP0#Y4155!A0`&P/>NE_:;UR+X??LPZ'X7TF6.26Z6"SF%NP<A$3>Y.W/5P,^
MN35?XF?$ZV^#^H6MKKWA"TLY;V,RQ!9!*&4'!Y5B!S5KXD>-A\)]*L[[7/!M
MI;6M^^R&2.990QQN_A8XXYJX)VI1M=)MK5:O_@`[7D_Z1-^RWX>\-_`[X-MX
MNUF:V75+^(SR$8DGAB)PD2*.<MP2.Y89X%=CX4^*/@S]KCPUJVA&WGRD>9;:
M[C5)HQG"S(02,@XY!R#C(YYY$Z_<-\/5\4Q^"+6?1G@%R)8I5D?RR<9V!MW'
M?CC!STKE/V08)O'?[1NN>*-.T]M/T5()%<*"(PS[0J>Y."V.V/I652BIJ=>3
M]Y;.ZT\BHRMRP6S_`*N9G[)EW=_"']IS4?"EU*3'=F>QD[*[Q9>-_P`0IQ_O
MT>/88_A?^W=:749$-O>ZC;SL?N@+.`LA/MEG-/M)E\0?\%!V>SY6/4V#%>G[
MJ`AS^:-3/VL@U_\`M;:1!;Q"ZG`L8Q"2%$C&3(3)Z9R/SKL7O5TW]J&ID](>
MC/IOQQ\8-`^'^CF\O;Y)@3M2&VQ-+*?0*I_4X`]:XKPO^V7X:\0:LEK<6&NZ
M2DC;5GNK9?*S[E&8@>Y&/I7+?$76[KX7:*=3UGP+##8!L/+"XG6+W?8QVCW/
M%</X=_:H\,^+]8AT_2O#<&HWUPVV."WC>21S]`:X*.!C*#:BY>=T;SK6E:]C
MZO7Q/IK8VZC8G/3$Z<_K17E-OX1U_P`V-CX#T]!N!)^V19'_`(_17&Z$%]K\
M5_F:\[[?F>R4445R&H5\JZ#^TM\:OVC/C1\2]*^%]K\*M#\.?"[Q$?"]TOBH
M7USJFJW200SR2A+=XUM8")@(V82F0*6P!@'ZJKX3_P""@'Q!^'7PHL?$W[0G
MPM^)G@_0?B[X&0V&J:?;ZK#+!X[-NQ4:#J%HC%Y+DD-'`X43PR,,$IN4@T?=
M49<QKO"AR.0#D9K$\"?$[P[\4/!D7B+PYKFEZWH,S3*FH6=RDULQAD>*4;P<
M922-U;^ZR,#@@U?\,:M-K_AO3K^>SGTZ>]MHYY+6;_6VS.@8QM_M*3@^XK\[
MOBIJ.M?"/XH_%O\`93\-RW-AJ/QY\20Z[X4N800=+T75UE;Q#.A'"FV>UOG7
MIA[ZWZYY`2/T(\`^/M$^*?@W3?$7AO5;#7-!UB!;FQU"RF6:WO(F^[)&Z\,I
M[$<&N*N_VR?A;9?&8?#Q_'&@MXS%PEF^EQS&26&X=0R02%0525E((C8AB#D`
MUW'@CP9I?PX\&:1X>T2SAT[1M"LX=/L;6(8CMH(D"1QJ/154#\*^.?#'Q/T?
M]CS]KS3+#P7XN\,>.OAU^T3XVNOM.B65_#=:MX8U^6"26>\@,;$S6,C6S"9'
MP;>1E*L58H`$C['\9>,M)^'7A+4M>UW4+32=%T>W>[O;VZD$<-K"BEGD=CP%
M`!))KS']C?\`;F^'?[='PVMO$7@37+2]=K6&ZO=,,\;WNDB7=L2X1&8(QV-Q
MDC@]:](^(NIRZ+\/M=O8$DDFM-/N)HT0;F9EB9@`.<G(]*\&_P""1?B?0M;_
M`.";_P`$[31M6TW4I=-\$:1'=);74<TEL_V505D"G*L&5Q@@'*D=C0![9\6?
MC+X4^!'@Z3Q!XS\0Z3X9T:*5(#=ZA<+#&TKG"1+GEY&/"HN68]`:I_!K]H/P
M3^T)I%Y?>"O$NE^(8-.F%M>K:R_OK&4J&$<T38>)BI!"NH)!S7RC_P`%'[:Z
MMOV[OV>]1UGQ^?AEX3@L==M]+\036%I=V5IX@D6T$$<INU:"*66U%VL+D!LB
M1%(,F#ZA^RC\`].T3]HWQE\1F^,R_%/Q1JFB6/A[58[>#3;>.UBAEFGMWFCL
MU7,N)I0K2<E#@<`8`L>V_$OXO>%?@SI-IJ'B[Q)HGABPO[M;"WN=4O([2&6=
ME9UB#N0-Q5'.,]%/I7FVB_\`!2#X#^(?"FL:W9_%?P5-IN@RPPWS_P!HHKPO
M-GR1Y9P[>9M;9M4[\';G!K@/^"H'A;2?B-K_`.SAX7UN"SO--UCXO:;/+:W,
M0ECNOLMC?W00J>""T0R"""!5;5O!.A>(?^"W6DZE=:;83:OX=^#4D]K.T0,L
M1FUGRMX/J$210>H$K@'YC0%CZ)^#/QR\'_M#^!H/$W@?Q'I/BG09Y'A6\T^X
M$T:R(</&V.4=3P48!AW`JI\;?VC?`W[.&BV6H>.?$^E>&[;4[C[+9"ZD_>WL
MVTL8X8U!>1@H)(120`3TKQK_`()W6ELWQ*_:;O[-84@O/BW>1E(E55$D6F:;
M'(<+_$74DD\DDD]:?^WSX/L+OQ1X/\<>'OB%X-\$_%SX76]]J>@P^([Z&+3]
M5L;A$CO+6[C9@ZV\OE1C[1'\T3HK#<`R,!8^@/`'C_1?BGX-T_Q#X=U*TUC1
M-6B\ZTO+9]\4Z9(R#]01CJ""*V*\E^`'[7WAKXQ?LR_#GXDZM+;>";;XD6UF
M;&RU>[CA=KRY'R6L;-M$KLP;9M&9%`8#G%>M4`PKR+]NS]HS4/V3?V6O$OC[
M2M-LM7U#19;&*&TNY&CAE-Q?6]L=Q7YA@3%N.I`KUVOEK_@L;./^&(+NU#1H
M^I>+?"]FA<X`9]>L!F@$M3ZEKQKXB?\`!0SX'_"BZGM]?^*7@VPN;2[N+&Y@
M_M!)9K6:WD\N=943<T?EO\K%@`I!!(KV6ODS_@D_X'T&+PG\:O%UC963:IXX
M^+?BJXU&[6(>;<K#J4UM%&S')*HD?"YP"SG`+'("1]/^"O&VC?$GPEIVO^'M
M5T_7-$U>!;FRO[&X6XMKN)AE7CD4E64CN#7/?&S]HWP)^SCHUE?^.O%6C>&+
M?4IOLUD+V<++?2@9,<,8R\K@<[4!.*\4_P"".]G;VO[">C/8HL6G7/B/Q)/9
M1(%6."!M=O\`8B!?E"*.`!P`*P?$/BGP[\/O^"PUQJ7Q#O\`3M(%_P##:TLO
M`%YJDJ06C2"^N6U6&WDD(071'V)F53O:(+U4'`%CZ4^%OQ:\(?M#^!$UWPIK
M&F>)]!N99+?S[<B2/S(VVO&P(RK*P(*L`0>HKHM.TFUTB(QVMM;VR,<E8HU0
M$^N!5#1O'>@Z]X8EUO3=8TJ^T:(2M)?6MU'-;+Y9(D)D4E?E*L&YX(.>E+X%
M\=Z+\3_!^F>(?#FJV&N:%K,"W5C?V4RSV]W$PRLD;J2&4CH1P::;V%8\$_X*
M*>%'N_#'A_6XT++97$EI*1V$BAES^*'\ZTM=T@_M,_L;6$ED!/J^FP(Z(.6:
M>`%'3ZLN[`_VEKUKXO?#R'XJ_#G5-"F*(;V+$4C#(BE'S(WT#`9]LU\H_LO_
M`!KG_9X^(%_X<\1K+:Z7=3F*Z5@2;&=3M\S']T]&QVP><<^QAG*IAU[/XJ;N
MO-')42C4][:1I_LG_M6VGPPTQO#7B7SH]+21FM;E4+FU).61E'.TG)R.02>Q
MX](^*W[:GA3P;X7GA\*31:IJDZGR1#`T<%NQ'WW)`SCK@9R>N*E^,?[&>@?%
M^\;7="U"/2;V^'G.\2":UNR>=^`1@GU4X.<XSDGE/!/_``3L6WU2.7Q!KRW%
MI&V3;V411I1GH7;H/H,^XZU<IX&I+VTVT^J\Q15:*Y%]Y2_8)^'%WJWB;5/&
MVHAS$BO;V\LG6:5SF5\GT'&?5SZ&L/P1??\`"\OVWO[3@_>V5M>M=(_4>3;K
MMC;\2J?BU>@_M3_';2OA#X$/@CPM]GAOY(?LTB6Y^7382.1_UT8$\=1DL><9
MD_8*^$$GA;PC=>)[V(I=:V!':AAADMP<[O\`@;8/T53WJYU7R3Q4U;F7+%>7
M]:DQCK&FNFK/H)E#J00"#U'K56PT*QTJ1WM;.UMGD^^T42H6^I`YJU17@IG;
M8****0PHHHH`*Y&7]G_P'/X\7Q5)X)\(OXG23S5U=M'MS?J^<[A/L\S.>^<U
MUU%`%77'O8M%O'TZ.VFU%8'-K'<.8X7EVG8KLH)52V,D`D#/!Z5X/\!/@%XZ
MU_\`:6UGXQ?%>'PO8>($T5/#'AC0]#O)=0MM!L#*)[J5[F6*%I;BYF6+)6)5
M2.WC49)8GZ"HH'<*Y7PS\#/!/@OQ==>(-&\'>%M)UZ]W"XU*STFW@O)]QRV^
M5$#MD]<DYKJJ*!!6!X&^%/A?X8&_/AGPUH'ATZI-]HO?[,T^&T^UR\_/)Y:C
M>W)Y;)YK?HH`S?%O@[2/'V@7&DZ[I6FZWI5V`L]G?VR7-O,`<@,C@JW/J*I?
M#[X5>%_A-I4EAX5\-Z!X9L97\Q[?2M/BLHG;^\5C503[XK?HH`J:EH%AK-Q9
MS7EE:7<VG3?:+5YH5D:VEVE=Z$C*MM9AD8.&([F@:#8C73J@LK0:F8/LIN_)
M7SS#NW>7OQNV;B3MSC)S5NB@"II6@V.A&Z-E96EF;V=KJX\B%8_/F8#=(^`-
MSG`RQR3@5A_$'X)^#/BS<6DOBKPCX8\32Z><VKZKI<%ZUL<YRAD5MO//%=/1
M0!Q/Q`_9]\+_`!0\;^!M>UJQ:[N?AS>RZEH<&_%K;73P-;B<Q?=9XXWD"$_<
M+DCG!';444!<*IZWX?L/$MFMMJ5C::A;+*DPBN85E0.C!T?#`C<K`,#U!`(Z
M5<HH`*IZ)X?T_P`-6CV^FV-GI]O)*\[1VT*Q(TCL6=R%`!9F))/4DDFKE%`%
M30]!L?#.F1V.FV5II]G"6*06T*Q1)N8LV%4`#+$DXZDD]ZS_`![\-?#GQ4T/
M^R_%&@:)XDTS>)/LFJ6,5Y!N'1MDBLN1D\X[UMT4`9?ASP3HO@[PQ#H>D:1I
MFE:+;HT46GV=K'!:QH2256-0%`))R`,')JUHVBV?AS2;:PTZTM;"PLXUAM[:
MWB6*&!`,!550`J@<``8%6J*`"O%/VI?V4HOC`AUG13%:^(H4"N'.V.^4#A6/
M9P.`WIP>Q'M=%:T:\Z4U.#LR9P4E9GP'H?Q-^(?[.5^^F+<:CI(C8YLKN(20
MGU*JP(P?5>M7O$7[8'Q"\:6WV%=5-J)_DVV%NL4CY[!@"P/T-?<NIZ-::W;^
M3>VMM>0G^":)9%_(BJFD>"=%\.RF33]'TRQD/\5O:QQ-^:@5ZBS.B_>G23E_
M7D<WU>2T4M#Y5_9U_8UU/QCJL.M^,()[+2U82K:39%Q?'.?G!Y1#WS\Q]LYK
MZ[@@CM8$BB18XHE"HBC"J`,``=ABGT5Y^*Q<Z\N:?R1O2I*"L@HHHKF-`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
?`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
